A61K 38/185
Nerve growth factor [ngf]
Official title: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
A61K38/185 (Nerve growth factor [ngf]) appears on 511 US grants and 871 published applications in this corpus.
Search patents in A61K- Granted patents
- 511
- Published applications
- 871
- Assignees
- 439
- Inventors
- 1,529
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 6 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 12 | 0 |
| 1998 | 26 | 0 |
| 1999 | 10 | 0 |
| 2000 | 20 | 0 |
| 2001 | 16 | 4 |
| 2002 | 16 | 28 |
| 2003 | 12 | 33 |
| 2004 | 11 | 34 |
| 2005 | 11 | 29 |
| 2006 | 9 | 35 |
| 2007 | 10 | 33 |
| 2008 | 7 | 38 |
| 2009 | 13 | 27 |
| 2010 | 13 | 27 |
| 2011 | 11 | 30 |
| 2012 | 27 | 26 |
| 2013 | 11 | 32 |
| 2014 | 31 | 36 |
| 2015 | 24 | 42 |
| 2016 | 28 | 41 |
| 2017 | 26 | 41 |
| 2018 | 23 | 52 |
| 2019 | 29 | 41 |
| 2020 | 21 | 47 |
| 2021 | 24 | 29 |
| 2022 | 15 | 37 |
| 2023 | 8 | 26 |
| 2024 | 14 | 40 |
| 2025 | 17 | 38 |
| 2026 | 5 | 25 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Targeting peptides for directing adeno-associated viruses (AAVs)16 Jun 2026US 12,653,904 B2California Institute of Technology
- Nerve guidance conduit comprising neural crest stem-like cells and/or Schwann cell precursor-like cells and methods of making and using the same14 Apr 2026US 12,599,634 B2The Trustees of the University of Pennsylvania
- Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation31 Mar 2026US 12,589,118 B2Ever Nuero Pharma GmbH
- Methods of treating epidermolysis bullosa with cell-free amniotic fluid compositions31 Mar 2026US 12,589,120 B2Eliksa Therapeutics, Inc.
- Supraparticle formulations17 Feb 2026US 12,551,450 B2The Bionics Institute of Australia
- Neurotrauma treatment1 Oct 2026US 2026/0295016 A1Ecole Polytechnique Federale De Lausanne (Epfl)
- Treatment of multiple sclerosis using nt-3 gene therapy1 Oct 2026US 2026/0295091 A1Research Institute At Nationwide Children's Hospital
- Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil) using a cerebrolysin® preparation24 Sep 2026US 2026/0284119 A1Ever Neuro Pharma Bmbh
- Methods of increasing therapeutic protein levels and/or improving cellular function with amniotic fluid compositions13 Aug 2026US 2026/0232737 A1Eliksa Therapeutics, Inc.
- Gene therapy for treating hearing loss disorders6 Aug 2026US 2026/0224745 A1Ohio Sate Innovation Foundation
Most cited
By later US patents
- Controlled release formulations of trophic factors in ganglioside-lipsome vehicle653US 5,073,543 AG. D. Searle & Co. · 1991
- Method and compositions for the treatment and repair of defects or lesions in cartilage470US 5,206,023 A1993
- Implantable biocompatable immunoisolatory vehicle for delivery of selected therapeutic products448US 6,083,523 ABrown University · 2000
- Methods and compositions for the treatment and repair of defects or lesions in cartilage399US 5,368,858 A1994
- Treatment of retinitis pigmentosa with human umbilical cord cells175US 7,413,734 B2Ethicon, Inc. · 2008